Anistreplase

DB00029ApprovedWithdrawnProtein Based Therapies

Anistreplase is a form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli. Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells.

Mechanism: Anistreplase cleaves the Arg/Val bond in plasminogen to form plasmin. This in turn leads to the degradation of blood clots.
Curator reviewed
Primary indication: For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarctionCurator reviewed
Formula / weight: C₂₅₆₉H₃₉₂₈N₇₄₆O₇₈₁S₄₀ · 59042.3 Da
First approval: Canada, 2002
Also known as: Anisoylated plasminogen streptokinase activator complex · APSAC
Code names: BRL-26921

Resolves to

Compound

UNII5O8V541HJ6CAS81669-57-0ChEMBLCHEMBL2108250

Clinical / RWD

RxNorm40028ATCB01AD03PharmGKBPA164769075

Targets

P00747PLGP02671FGAP05121SERPINE1

What you can answer from here — as of July 17, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

705Drug interactionsStructured to mechanism, not free text

1Marketed productAcross 1 country and 1 labeller

1ATC codeIncluding every combination product, plus 18 drug categories

12+ReferencesStructured and connected to the statements they support

Which drugs share a target with Anistreplase, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account